Nowadays, mixed liver tumors are more frequently diagnosed due to better imaging, advanced immunohistochemistry (IHC) staining techniques and better knowledge of hepatic tumorigene- sis [1–3] . Such tumors represent ...Nowadays, mixed liver tumors are more frequently diagnosed due to better imaging, advanced immunohistochemistry (IHC) staining techniques and better knowledge of hepatic tumorigene- sis [1–3] . Such tumors represent a mosaic of components with dis- tinct histogenesis and carcinogenic pathways. As their occurrence in the liver is very rare, their behavior and natural history are difficult to determine, and their management remains empirical. An uncommon case of a composite tumor harboring hepatocellular carcinoma (HCC) and hepatic hemangiosarcoma (HHS) components in a liver transplant (LT) recipient is reported herein.展开更多
Current treatments for inflammatory bowel disease(IBD)treatment consist of anti-inflammatory products.In this study,we sought to induce the physiological secretion of glucagon-like peptide 2,a peptide with intestinal ...Current treatments for inflammatory bowel disease(IBD)treatment consist of anti-inflammatory products.In this study,we sought to induce the physiological secretion of glucagon-like peptide 2,a peptide with intestinal growth-promoting activity,via nanoparticles while simultaneously providing with immunomodulation by tailoring the nanoparticle surface.To this end,we developed hybrid lipid hyaluronate-KPV conjugated nanoparticles loaded with teduglutide for combination therapy in IBD.The nanocarriers induced(or did not induce)immunosuppression depending on the presence(or absence)of a hyaluronan-KPV functionalization.This strategy holds promise as a nanoparticle platform for combined mucosal healing and immunomodulation in IBD treatment.展开更多
文摘Nowadays, mixed liver tumors are more frequently diagnosed due to better imaging, advanced immunohistochemistry (IHC) staining techniques and better knowledge of hepatic tumorigene- sis [1–3] . Such tumors represent a mosaic of components with dis- tinct histogenesis and carcinogenic pathways. As their occurrence in the liver is very rare, their behavior and natural history are difficult to determine, and their management remains empirical. An uncommon case of a composite tumor harboring hepatocellular carcinoma (HCC) and hepatic hemangiosarcoma (HHS) components in a liver transplant (LT) recipient is reported herein.
基金Belgian F.R.S.-FNRS(Fonds de la recherche scientifique)under grants WELBIO-CR-2022A-02The Excellence Of Science(EOS:program no.EOS 30770923 and 40007505)+4 种基金supported by the Marie Skłodowska-Curie Actions for an Individual European Fellowship under the European Union’s Horizon 2020 research and innovation program(grant agreement no.887609)by a FRS-FNRS fellowship(grant agreement no.40000747)(Belgium)partially supported by the FRS-FNRS(convention T.0013.19)FRFS-WELBIO,with the support of the Wallon region(under grant agreement WELBIO-CR-2022 S-01)has received funding from the European Research Council(ERC)under the European Union’s Horizon 2020 research and innovation program(grant agreement No.850997-NanoGut).
文摘Current treatments for inflammatory bowel disease(IBD)treatment consist of anti-inflammatory products.In this study,we sought to induce the physiological secretion of glucagon-like peptide 2,a peptide with intestinal growth-promoting activity,via nanoparticles while simultaneously providing with immunomodulation by tailoring the nanoparticle surface.To this end,we developed hybrid lipid hyaluronate-KPV conjugated nanoparticles loaded with teduglutide for combination therapy in IBD.The nanocarriers induced(or did not induce)immunosuppression depending on the presence(or absence)of a hyaluronan-KPV functionalization.This strategy holds promise as a nanoparticle platform for combined mucosal healing and immunomodulation in IBD treatment.
